Biotech catalyst, news and analysis PDUFA tracker
Iovance Biotherapeutics
A source-verified Q2 2026 deep dive into Geron, Novavax and Iovance: revenue quality, cash, dilution, pipelines, regulation, competition, valuation and catalysts.
The FDA’s second no on RP1 plus nivolumab in advanced melanoma does not look like a simple administrative delay. It is a rejection that hits the core regulatory thesis, reopens the debate around the program’s near-term value and forces a broader reassessment of the Replimune story as a strategic reset rather than a delayed approval thesis.
Iovance enters the next stretch in a very different place than where the bull case used to live. The stock still has a powerful story behind it: AMTAGVI is already commercial, the TIL platform is no longer theoretical, and the company is trying to push that proof into larger and commercially more meaningful opportunities such as NSCLC. But this is also a company that the market punished hard when execution, European regulatory ambition and financing optics stopped matching the earlier narrative. That history matters because it explains why each new positive data point now has to pass a tougher test with investors.
As of February 24, 2026, Iovance Biotherapeutics is a small-cap oncology company (~$1.5B market cap) focused on TIL cell therapies for solid tumors, with AMTAGVI (lifileucel) already approved in the U.S. for advanced melanoma and a growing pipeline exploring TIL in other indications, including soft-tissue sarcomas.
The stock trades around $3.80 with roughly 364M shares outstanding, after a volatile path that has seen heavy dilution in past years but now combines commercial revenues (~$264M FY25) with a cash runway into Q3 2027 thanks to cost controls and better gross margins on AMTAGVI. The new 50% objective response rate (ORR) in the very difficult setting of advanced UPS/DDLPS sarcomas is what the market is reacting to right now.
A parallel “year of truth” roadmap for Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX) and Altimmune (ALT), three names with huge retail followings, real science on the table and very little room for execution mistakes.
Iovance Biotherapeutics (IOVA) – From first TIL approval to industrial stress-test in solid tumors (Playbook 2026–2027) | Merlintrader trading Blog Merlintrader trading Blog – RunUP Biotech EN IT IOVA – Iovance Biotherapeutics (NASDAQ) Static daily chart from Finviz – click…
6 November 2025 – Iovance reports Q3 2025 revenue of about $68 million, up 13% sequentially, with Amtagvi driving the growth. Gross margin improves to 43%, but the company still posts a net loss of over $90 million and burns cash.
